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Abstract
Conotruncal heart defects (CTDs) are among the most severe birth defects worldwide. Studies of CTDs indicate both lifestyle
behaviors and genetic variation contribute to the risk of CTDs. Based on a hybrid design using data from 616 case-parental
and 1645 control-parental triads recruited for the National Birth Defects Prevention Study between 1997 and 2008, we
investigated whether the occurrence of CTDs is associated with interactions between 921 maternal and/or fetal single
nucleotide polymorphisms (SNPs) and maternal obesity and tobacco use. The maternal genotypes of the variants in the
glutamate-cysteine ligase, catalytic subunit (GCLC) gene and the fetal genotypes of the variants in the glutathione S-
transferase alpha 3 (GSTA3) gene were associated with an elevated risk of CTDs among obese mothers. The risk of delivering
infants with CTDs among obese mothers carrying AC genotype for a variant in the GCLC gene (rs6458939) was 2.00 times
the risk among those carrying CC genotype (95% confidence interval: 1.41, 2.38). The maternal genotypes of several variants
in the glutathione-S-transferase (GST) family of genes and the fetal genotypes of the variants in the GCLC gene interacted
with tobacco exposures to increase the risk of CTDs. Our study suggests that the genetic basis underlying susceptibility of
the developing heart to the adverse effects of maternal obesity and tobacco use involve both maternal and embryonic
genetic variants. These results may provide insights into the underlying pathophysiology of CTDs, and ultimately lead to
novel prevention strategies.
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Introduction
Congenital heart defects (CHDs) are among the most common
and severe birth defects worldwide, with reported estimated
prevalence of 9.1 per 1,000 live births after 1995 [1]. Conotruncal
heart defects (CTDs), a class of CHDs, affect the cardiac outflow
tracts and great arteries which include truncus ateriosus,
interrupted aortic arch type B, transposition of great arteries,
double outlet right ventricle, conoventricular septal defect,
tetralogy of Fallot, and pulmonary atresia with ventricular septal
defect.
Nonsyndromic CTDs are due to a multifactorial etiology
involving a complex interplay between genetic susceptibilities and
environmental factors [2,3]. One such interplay is between
maternal folic acid supplement use and genetic variants in
folate-related pathways. Based on the finding that maternal
periconceptional folic acid intake decreases the occurrence of
CTDs [4,5], multiple studies have investigated associations
between CTDs and polymorphisms in folate-related genes [6–8].
It has also been reported that genetic variants in folate-related
pathways modify the association between birth defects and
maternal intake of folic acid containing supplements [9].
Developmental toxicology studies using animal models have
repeatedly demonstrated the unquestioned importance of genetic
variation in determining risks to environmental factors [10].
Inbred strains of mice, representing different mouse genomes, vary
in their susceptibility to teratogenic and xenobiotic agents. In
reproductive age women, obesity and tobacco use have been
associated with multiple adverse outcomes including intrauterine
growth retardation [11,12], prematurity [13,14], and birth defects
[15–17]. Obesity and cigarette smoking are also associated with
alterations in folate and glutathione metabolism resulting in
decreased folate [18,19], increased homocysteine [20–24], and
decreased glutathione [25–30] that may compromise the in-utero
environment. Some studies have demonstrated that maternal
genetic variants modulate the association between pregnancy
smoking exposure and fetal growth restriction [31,32]. It is
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possible that variants in genes that encode for critical enzymes in
folate, homocysteine and glutathione pathways modify the adverse
impact of obesity and tobacco on the developing heart.
In this study, we used a hybrid design which combines genetic
and lifestyle data from case-parental and control-parental triads to
investigate whether CTDs are associated with interactions
between maternal and/or fetal single nucleotide polymorphisms
(SNPs) and maternal obesity and tobacco use. In contrast to most
published reports of Gene 6 Environment (G 6 E) interactions
[4,33,34], we have evaluated maternal and fetal genetic effects
simultaneously. A total of 1536 SNPs in 62 target genes were
selected for this study from folate-related metabolic pathways.
Materials and Methods
Study Population
Families were recruited for the National Birth Defects
Prevention Study (NBDPS) with estimated dates of delivery
between October 1997 and August 2008 (www.nbdps.org).
Detailed information about the NBDPS is outlined in Yoon et al
[35]. Families were identified through population-based birth
defects surveillance systems in 10 states: Arkansas, California,
Iowa, Massachusetts, New Jersey (through 2002), New York,
Texas, Georgia, North Carolina (beginning 2003), and Utah
(beginning 2003). In this study, cases were singleton live-born
infants with CTDs. NBDPS cardiac cases were reviewed by
pediatric cardiologists using a classification strategy developed by
investigators within the NBDPS. This strategy targeted etiologic
investigations of CHDs that encourage explicit case definitions and
aggregates of defects with a focus on simple, isolated phenotypes
and associations [36]. Cases with recognized or strongly suspected
monogenic or chromosomal conditions were excluded. Controls
were singleton live-born infants without any major structural birth
defects [37]. Both case and control mothers completed phone
interviews. The study was approved by the University of Arkansas
for Medical Sciences’ Institutional Review Board and the NBDPS
with protocol oversight by the Centers for Disease Control and
Prevention Center for Birth Defects and Developmental Disabil-
ities. All of the study subjects gave written informed consent. For
minors, informed written consent was obtained from their legal
guardian.
Maternal Interview
Participation in the NBDPS included a one-hour interview with
mothers of cases and controls, conducted in English or Spanish, by
interviewers using a computer-assisted telephone questionnaire
[35]. In this study, we investigated how maternal obesity and
tobacco use modify maternal and fetal genetic effects on the risk of
CTDs. Obesity, using the Institute of Medicine definition [38],
was defined as a body mass index (BMI) $30.0 and normal weight
between 18.5 and 25.0. Smokers were defined as women who
smoked cigarettes during the 3 months after conception and
nonsmokers otherwise. Maternal use of folic acid supplements is a
known risk factor for the occurrence of CTDs and warranted a
separate manuscript [9].
DNA Collection
After completion of maternal interviews, a buccal cell collection
kit was sent to participants to obtain cheek cell samples from case/
control and parents. The collection kit included informed consent
forms, instructions, $20 money order, materials for completing the
specimen collection and prepaid US mail packets for specimen
return [35].
Gene/SNP Selection
As previously described [39], a custom panel of 1536 SNPs in
62 genes involved in folate metabolism was developed jointly
between our lab and Illumina. Candidate genes were required to
encode an enzyme in one of the candidate metabolic pathways
and be expressed in liver and/or heart tissue [40]. For each
candidate gene, a maximally informative set of haplotype-tagging
SNPs was selected using both linkage disequilibrium statistics and
Illumina assay design scores. The custom genotyping panel was
devised in 2005–2006. At that time there were two genes called
RFC1 in the commonly used genetic databases. The genotype
data presented here are for SNPs in the Replication Factor C
(activator 1) 1 (RFC1) gene. This gene is an activator of DNA
polymerase and is required for DNA synthesis and repair.
Genotyping and Quality Assessment
Genotyping was conducted on a total of 635 case and 1702
control families using 200 ng of WGA DNA on the Illumina
Golden Gate platform [41]. Initial genotype calls were generated
using Genome Studio’s GenCall, Illumina’s proprietary algorithm,
with subsequent analysis performed using SNPMClust, a bivariate
Gaussian model-based genotype clustering and calling algorithm
developed in-house. A total of 297 individuals were removed due
to study ineligibility (n = 33), high no-call rates (n = 63), or high
rates of Mendelian inconsistency (n = 201). We found that the
quality of genotype clustering varied substantially from SNP to
SNP, which we attribute to the in silico design of the SNP panel
based on data from phases I and II of the HapMap project,
without the subsequent quality checks that would be applied to a
standard commercial SNP panel. While the majority of SNPs
exhibited well-segregated genotype clusters, a substantial percent-
age exhibited poor clustering and/or lower minor allele frequency
(MAF) than expected. To ensure high-quality genotypes, we
applied stringent quality control measures and excluded SNPs with
obviously poor clustering behavior (60 SNPs), no-call rates .10%
(328 SNPs), Mendelian error rates .5% (11 SNPs), MAF ,5%
(204 SNPs), or significant deviation from Hardy-Weinberg
Equilibrium in at least one racial group (p,1024, 12 SNPs).
The final dataset included 4648 individuals, each with 921 SNPs.
Statistical Methods
Descriptive statistics were summarized for families. Compari-
sons of maternal characteristics were carried out between case and
control families using the two-sample t-tests for continuous
variables and chi-square tests for categorical variables. Because
both case-parental and control-parental triads were enrolled and
genotyped, a hybrid design provided optimal power by using a log-
linear model [42]. This model has several advantages including
incorporating case and control triads, providing population-based
inferences related to maternal and fetal genetic effects, providing
evidence related to fetal genetic effects that are robust to
population admixture, and allowing inclusion of missing genotype
data. To assess Gene 6Environment (G 6E) interactions, a log-
linear model was fitted for each SNP as a function of mating types,
an interaction between mating types and a maternal factor (E),
case/control status (D), maternal genotype (D6M), fetal genotype
(D 6C), an interaction for maternal genotype (D 6E 6M), and
an interaction for fetal genotype (D 6 E 6 C). The detailed
information regarding the model is outlined in Hobbs et al [9].
Based on the log-linear model for counts and assuming a Poisson
distribution, the relative risk (RR) (95% CI) of having one copy of
the minor allele compared to no copy was estimated for each SNP.
Because we assumed multiplicative risk of alleles, the estimated
RR (95% CI) of having 2 copies of the minor allele is square of the
CTDs and Gene 6 Environment Interactions
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estimated RR (95% CI) of having 1 copy of the minor allele. We
also performed sensitivity analysis by restricting our models to the
Caucasian families only. The Caucasian families were selected for
the sensitivity analysis because among all the racial groups, we had
the largest sample size for Caucasian families. For other racial
groups, we did not have power to perform any subgroup analyses.
The Bayesian false-discovery probability (BFDP) [43–48] was
used to evaluate the chance of false-positive associations using
estimates of the RR and corresponding 95% CI obtained from log-
linear models. In the results section, we reported associations
where BFDP ,0.80, which is a commonly used threshold
suggested by Wakefield [43] for summary analyses. Patterns of
linkage disequilibrium (LD) between significant SNPs in the same
gene were constructed to assess the correlations among these SNPs
using the parents of control families. Data were analyzed using
statistical software LEM [49] for fitting log-linear models, R v3.0.1
(R Foundation for Statistical Computing, Vienna, Austria) for
computing descriptive statistics, and BFDPs and HaploView 4.2
[50] for developing LD maps.
Results
Study Sample
A total of 616 case families and 1645 control families were
included in our analysis. Due to different call rates among SNPs,
case and control triads/dyads/monads numbers differ for any
given SNP. Maternal demographics and lifestyle factors are
summarized in Table 1. The case mothers were slightly older
than the control mothers [28.366.1 vs. 27.566.0, p = 0.002].
Case and control mothers did not differ on any of the other
demographics and lifestyle characteristics (p.0.05).
Genetic Variants
As described above, 921 candidate SNPs were included in the
final analyses. The information about the number of SNPs in each
gene, chromosome and pathway is displayed in Figure 1. Hobbs
et al. [9] identified the maternal genotypes of 17 SNPs and the
fetal genotypes of 17 SNPs associated with CTD risks indepen-
dently from interactions with maternal folic acid supplement use,
obesity and tobacco use. Briefly, the maternal genotypes of 10
SNPs and the fetal genotypes of 2 SNPs in the glutamate-cysteine
ligase, catalytic subunit (GCLC) gene were found to be significantly
associated with the risk of CTDs through main genetic effects [9].
Gene 6 Environment Interactions
In Hobbs et al. [9], we identified SNPs that had a main effect on
the occurrence of CTDs. To identify significant G 6 E
interactions, we evaluated the combined effects of each maternal
and infant SNP with maternal folic acid supplement use, obesity
and tobacco use. Significant interactions are discussed below.
SNP 6Folic Acid Supplement Use. In Hobbs et al. [9], we
have studied the interactions between 921 SNPs and periconcep-
tional folic acid supplement use, and found that the maternal
genotypes of 19 SNPs and the fetal genotypes of 9 SNPs had
BFDP ,0.80 for testing the G 6E interactions with maternal use
of folic acid supplements. All these SNPs were not found to be
significant based on the gene only models. Detailed information
about the SNP 6 folic acid supplement use is outlined in Hobbs
et al [9].
SNP 6 Obesity. A main effect of the association between
CTDs and obesity compared to normal weight resulted in an
estimated RR = 1.27 (95% CI: 0.99, 1.63; p = 0.06). Because
previous studies showed that obesity independent of pre-existing
Type I or Type II diabetes was significantly associated with
elevated risk of CTDs [15,51], we computed a model for each
SNP among normal-weight and obese women. The results are
shown in Figure 2 and Table S1.
Among 10 maternal SNPs with a significant gene 6 obesity
interaction, three SNPs are in the GCLC gene, three SNPs are in
the O-6-methylguanine-DNA methyltransferase (MGMT) gene,
and the remaining four SNPs are in the glutathione S-transferase
mu 2 (GSTM2), transcobalamin II (TCN2), cystathionine-beta-
synthase (CBS), and DNA (cytosine-5-)-methyltransferase 3-like
(DNMT3L) genes respectively. The most significant maternal gene
6 obesity interaction (i.e. most significant difference in the
estimated RR for certain genotype among obese women
compared to normal weight women) was embedded in the GCLC
gene. The genotype of rs6458939 was not associated with the risk
of CTDs among normal-weight women [estimated RR: 0.89, 95%
CI: 0.70, 1.12]; however, the risk of delivering infants with CTDs
among obese women carrying AC genotype for rs6458939 was
estimated to be 2.00 (95% CI: 1.41, 2.83) times the risk among
those carrying CC genotype. The RR (95% CI) for carrying two
copies of the minor allele is square of the estimated RR (95% CI)
for carrying one copy of the minor allele. Thus, only the RR (95%
CI) is reported for carrying one copy of the minor allele compared
to no copy of the minor allele. A similar pattern was observed for
the maternal genotypes of two other SNPs in the GCLC gene. All
three maternal SNPs in the GCLC gene were determined to be in
high LD (D9$0.98).
Among 10 fetal SNPs found to be associated with the risk of
CTDs in combination with obesity, three SNPs reside in the
glutathione S-transferase alpha 3 (GSTA3) gene, three SNPs are in
the adenosylhomocysteinase-like 2 (AHCYL2) gene, three SNPs
are in the DNA (cytosine-5-)-methyltransferase 3 alpha
(DNMT3A) gene, and the other SNP resides in the GCLC gene.
We observed the most significant difference in the fetal effect of the
GSTA3 gene on the risk of CTDs between normal-weight and
obese women. The risk of CTDs was elevated for infants with AG
genotype for rs668163 compared to GG genotype among obese
women (RR: 1.83, 95% CI: 1.33, 2.52), but was not significantly
reduced among normal-weight women (RR: 0.94, 95% CI: 0.75,
1.18). Similar findings were observed for the fetal genotypes of two
other SNPs in the GSTA3 gene. All three fetal SNPs in the GSTA3
gene were in high LD (D9$0.96).
Similar results were observed when overweight women were
compared to normal-weight women (data not shown) and based
on Caucasian families only (data not shown). There was no main
effect of any of the SNPs discussed above.
SNP 6 Tobacco Use. A main effect of the association
between CTDs and maternal tobacco use compared to no tobacco
use had an estimated RR = 1.08 (95% CI: 0.85, 1.37; p = 0.54).
We investigated the interactions between SNPs and maternal
tobacco use on the occurrence of CTDs by fitting the G 6E log-
linear model with maternal tobacco use for each SNP. The
maternal and fetal SNPs that had a significant interaction with
maternal tobacco use are presented in Figure 3 and Table S2.
Among 6 maternal SNPs found to have BFDP ,0.80, two of
them are located in the RFC1 gene, two SNPs are in the
glutathione S-transferase alpha 4 (GSTA4) gene, and the other two
SNPs are in the glutathione S-transferase alpha 1 (GSTA1) and
glutathione S-transferase alpha 2 (GSTA2) genes respectively. The
GSTA1, GSTA2 and GSTA4 genes are glutathione-S-transferase
(GST) family of genes. The RRs of the maternal AC genotype for
rs2397135 in the GSTA4 gene compared to CC genotype were
estimated to be 0.92 (95% CI: 0.76, 1.11) among women without
tobacco use, and 1.74 (95% CI: 1.21, 2.49) among women with
CTDs and Gene 6 Environment Interactions
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tobacco use, interaction BFDP = 0.68,0.80. The two maternal
SNPs in the RFC1 gene were in moderate LD (D9 = 0.82).
Among 5 fetal SNPs identified to have BFDP ,0.80, three
SNPs are in the GCLC gene, one SNP (rs11727502) is in the
RFC1 gene, and the other SNP (rs10277237) is located in the
nitric oxide synthase 3 (endothelial cell) (NOS3) gene. The RRs of
the fetal AG genotype for rs7742367 in the GCLC gene compared
to AA genotype were estimated to be 1.14 (95% CI: 0.83, 1.40)
among women without tobacco use, and 2.12 (95% CI: 1.48, 3.04)
among women with tobacco use, interaction BFDP = 0.71,0.80.
The two fetal SNPs (rs7742367 and rs10948751) in the GCLC
Table 1. Maternal characteristics for 616 case families and 1,645 control families enrolled in National Birth Defects Prevention
Study between 1997 and 2008.
Case Control
(N = 616) (N = 1,645)
Age at delivery (years) 28.366.1 27.566.0
Race
African American 49 (8%) 143 (9%)
Caucasian 401 (66%) 1,136 (69%)
Hispanic 123 (20%) 285 (17%)
Others 39 (6%) 78 (5%)
Missing information 4 3
Education
,12 years 83 (14%) 217 (13%)
High school degree or equivalent 167 (27%) 413 (25%)
1–3 years of college 173 (28%) 454 (28%)
At least 4 years of college or Bachelor degree 190 (31%) 559 (34%)
Missing information 3 2
Household income
Less than 10 Thousand 94 (16%) 236 (15%)
10 to 30 Thousand 150 (26%) 408 (27%)
30 to 50 Thousand Dollars 118 (20%) 348 (23%)
More than 50 Thousand 217 (37%) 538 (35%)
Missing information 37 115
Folic acid supplements
No 299 (49%) 738 (45%)
Yes1 314 (51%) 907 (55%)
Missing information 3 0
BMI
Underweight (BMI ,18.5) 31 (5%) 74 (5%)
Normal weight (18.5, = BMI ,25) 298 (50%) 880 (55%)
Overweight (25, = BMI ,30) 141 (24%) 360 (23%)
Obese (. = 30) 121 (20%) 281 (18%)
Missing information 25 50
Alcohol consumption
No 460 (76%) 1,251 (76%)
Yes2 149 (24%) 390 (24%)
Missing information 7 4
Tobacco use
No 498 (81%) 1,356 (82%)
Yes3 114 (19%) 288 (18%)
Missing information 4 1
Summary statistics were expressed as mean 6 standard deviation for continuous variables, and frequency (percentage) for categorical variables.
1Folic acid supplements yes is defined as maternal use of folic acid supplements at least two months during the exposure window (i.e. one month prior to conception
and two months after conception).
2Alcohol consumption yes is defined as drinking during the three months after pregnancy.
3Tobacco use yes is defined as cigarette smoking during the three months after pregnancy.
doi:10.1371/journal.pone.0108903.t001
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Figure 1. SNP, gene, chromosome and pathway information. Information about the number of SNPs from each gene, chromosome and
pathway (* there are a total of 142 candidate SNPs on MGMT, truncated at 50 for display purpose). The average number of SNPs per gene is 15619.
Among 60 genes, 10 (17%) genes are involved in folate pathway, 32 (53%) in glutathione pathway, and 17 (28%) in homocysteine pathway, and one
gene RFC1 (2%) in DNA synthetic/repair pathway.
doi:10.1371/journal.pone.0108903.g001
Figure 2. Interactions between gene and obesity. The estimated relative risks and their 95% confidence intervals for each maternal and fetal
SNPs that were identified to have a significant interaction with maternal obesity on the risk of CTDs. (A) Maternal genetic effects among normal-
weight women; (B) Maternal genetic effects among obese women; (C) Fetal genetic effects among normal-weight women; (D) Fetal genetic effects
among obese women.
doi:10.1371/journal.pone.0108903.g002
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gene were in high LD (D9 = 0.99), and in moderate LD with the
other SNP (rs2284650) respectively (D9 = 0.89 and 0.93).
Similar results were found based on Caucasian families only
(data not shown). There was no SNP main effect.
Discussion
This study provides evidence for a moderating effect of multiple
SNPs related to one-carbon metabolism and glutathione metab-
olism on the relationship between CTDs and maternal obesity and
tobacco use. Significant genes and their pathway information are
displayed in Figure 4. Our findings support the hypothesis that
CTDs are associated with G 6 E interactions between common
genetic variants and lifestyle factors. Consistent with previous
studies [52–54], our results provide supportive evidence that both
maternal and fetal genotypes modify the susceptibility of the
developing fetus to factors that may alter the in-utero environ-
ment.
Maternal obesity independent of diabetes is a well-accepted risk
factor for multiple nonsyndromic birth defects including CTDs
[15,51,55]. Among obese women, the maternal genotypes of 10
SNPs within 6 genes (GCLC, MGMT, GSTM2, TCN2, CBS, and
DNMT3L) and the fetal genotypes of 7 SNPs within 3 genes
(GSTA3, AHCYL2, and DNMT3A) were associated with an
increased risk of CTDs, whereas, among women of normal weight,
none of the maternal genotypes had a significant impact on the
RR, and the fetal genotypes of 4 SNPs in 2 genes (AHCYL2 and
GCLC) decreased the risk of CTDs.
Among women who used tobacco in the periconceptional
period, the maternal genotypes of 6 SNPs in 4 genes (RFC1,
GSTA4, GSTA1, and GSTA2) were associated with an increased
risk of CTDs. The GST genes function in the detoxification of
several environmental exposures, including carcinogens, medica-
tions, and factors increasing oxidative stress. The fetal genotypes of
5 SNPs in 3 genes (GCLC, RFC1 and NOS3) increased the
occurrence of CTDs among women who smoked. None of the
maternal or fetal genotypes significantly impact the risk among
women without tobacco use.
Our findings compel us to comment on some of the findings in
the context of previous studies. Several maternal and fetal
genotypes of SNPs in the glutathione transferase (GSTA4,
GSTA1, GSTA2, GSTM2, and GSTA3) genes increased the
impact of maternal obesity and tobacco use on the risk of CTDs.
The Glutathione S-transferase complex of genes are involved in
the detoxification of a large number of xenobiotics including
chemical compounds in tobacco smoke [56]. Genetic variants in
Figure 3. Interactions between gene and maternal tobacco use. The estimated relative risks and their 95% confidence intervals for each
maternal and fetal SNPs that were identified to have a significant interaction with maternal tobacco use on the risk of CTDs. (A) Maternal genetic
effects among non-smokers; (B) Maternal genetic effects among smokers; (C) Fetal genetic effects among non-smokers; (D) Fetal genetic effects
among smokers.
doi:10.1371/journal.pone.0108903.g003
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glutathione S-transferase genes may be a factor in determining
individual susceptibility to embryotoxic effects of xenobiotics,
including tobacco. Lending credence to the possibility that
glutathione S-transferases in interaction with tobacco may impact
the developing fetus, is a report that glutathione S-transferase
genetic variants modified the impact of cigarette smoking on birth
weight [32].
In earlier reports [57,58], we demonstrated that women who
had infants with CHDs had lower GSH levels. GSH level is
essential for cell progression and serves several functions that are
crucial during embryogenesis. GSH is important in the defense
against oxidative stress, detoxification of xenobiotics, regulation of
cell cycle progression and apoptosis, and modulation of immune
function [56]. GCLC is the gene that encodes for the catalytic
subunit glutamate-cysteine ligase, which is the enzyme that
catalyzes the conversion of cysteine with glutamate, generating
glutathione. Several maternal and fetal genotypes of SNPs in the
GCLC gene increased the RR of CTDs among women who
smoked and/or were obese.
Among women who did not use folic acid supplements, 8 SNPs
in the hematopoietic prostaglandin D synthase gene (HPGDS)
increased the risk of CTDs, but had no associated increased risk
among folic acid supplement users [9]. HPGDS is a member of the
sigma class of glutathione S-transferase gene family. The HPGDS
gene catalyzes both isomerization of PGH (2) to PGD (2) and
conjugation of glutathione to 1-chlore-2, 4-dinitrobenzene [59–
61]. HPGDS is present in mast cells, macrophages and other
cellular sources [62]. Little is known about the impact of
prostaglandin synthase on the development of CHDs. Previous
studies have shown that HPGDS plays a role in multiple
physiological processes that are important during embryogenesis,
including detoxification of xenobiotics [63], regulation of inflam-
matory pathways [59] and modification of reactive oxygen species
[64]. Animal models and mechanistic studies are needed to
Figure 4. Significant genes and their pathways. Related pathways include the folate pathway, which is involved in DNA synthesis, and the
methionine and glutathione pathways, which are necessary for DNA methylation and for conjugation of electrophilic substrates, respectively.
Substrates and products of enzymatic reactions appear in boxes. Enzymes appear in color-coded bubbles according to their association with birth
defects risk and maternal folic acid supplement use (Green), obesity (Purple) and tobacco use (Blue).
doi:10.1371/journal.pone.0108903.g004
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validate and clarify the role of maternal HPGDS in the
development of heart defects.
There are several strengths of this study including the use of log-
linear models based on a hybrid design, its large sample size,
population-based ascertainment of cases, and a rigorous analytic
inquiry into potential G6E interactions on CTD risks. There are
also limitations in our study. No adjustment was made for
confounding effects from other exposures when fitting the model,
which prohibited us from drawing further conclusions about the
observed associations. Other limitations related to DNA and
lifestyle data collection existed. The usage of buccal cell collection
kits in collecting DNA samples created a disparity among the
quality of the DNA samples, resulting in a reduction from 1534 to
921 candidate SNPs. Maternal obesity and tobacco use were self-
reported, and not objectively measured.
It is now generally accepted that most CHDs are the result of a
complex interplay between genetic and environmental factors.
Our results suggest that, in the search for genetic variants related
to CTDs, accounting for environmental and lifestyle factors may
improve the ability to detect genetic effects. Because the typical
effect size for maternal and fetal genetic variation acting on CHD
phenotypes is small [65,66], large sample sizes and validation
within independent populations are necessary to draw firm
conclusions about how certain polymorphisms modulate the
experience of maternal lifestyles. The present findings will need
to be replicated and further studies should incorporate functional
genetics and targeted deep sequencing while enhancing informa-
tion collected on environmental and lifestyle factors. One
limitation of our current study is that to properly assess the
accuracy of our findings, they will need to be replicated on a fully
distinct and independent sample [67]. Nevertheless, our study is
the largest family-based case-control study of CTDs ever
conducted in the U.S., and to our knowledge, there is no
comparable, independent sample which includes the maternal and
fetal genotype data, and maternal lifestyle and demographic data,
necessary to validate our results.
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